Ralphy, I doubt the FDA would have allowed them to run a trial with an arm not getting a statin. One arm is not getting proper treatment. Now, if V shows success, I can see another shorter trial done by the likes of the NIH comparing 2 proven drugs.
Perhaps it's called taking 4 grams of Vascepa by itself. 38 posts of defensive posturing without much substance. Some around here will keep feeding you chum, they can't help it.
In statin naive patients there may have been much better potential for success than in patients already taking - and success here would have opened the door for direct competition against statins
THIS IS A MAJOR FLAW AND MAY COST INVESTORS HUGELY
If R-IT is with statin naive patients and successful: Would you (prescribers) like (have enough proof) to subscribe V as add-in for patients already taking statin? Or not?
If R-IT is with statin naive patients and successful: Would you (prescribers) like (have enough proof) to subscribe V instead of statin? Or not?
If R-IT (as it is) is successful: Would you (prescribers) like (have enough proof) to subscribe V for statin naive patients? Or not?
If you answer honestly, you will know why is the design (patients already taking statin) what it is.